GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Spero Therapeutics
Shares of Spero Therapeutics, a biopharmaceutical company focused on treating antibiotic-resistant infections, reflect the sector's binary risks. The price trajectory depends entirely on the results of clinical trials and regulatory decisions regarding its drugs.
Share prices of companies in the market segment - Pharma infections
Spero Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel treatments for multidrug-resistant bacterial infections. We classify it as "Pharmaceuticals (Infections)." The chart below shows the dynamics of this critically important segment.
Broad Market Index - GURU.Markets
Spero Therapeutics is a biotech company developing drugs to treat antibiotic-resistant bacterial infections. As an innovator in this field, it is included in our GURU.Markets index. The chart below reflects the overall stock market performance. Compare it to Spero's stock to assess the outlook for the biotech sector.
Change in the price of a company, segment, and market as a whole per day
SPRO - Daily change in the company's share price Spero Therapeutics
Spero Therapeutics' daily share price fluctuations reflect the extreme volatility inherent in biotech companies battling antibiotic-resistant bacteria. This metric is a measure of the company's sensitivity to clinical trial data and FDA decisions.
Daily change in the price of a set of shares in a market segment - Pharma infections
Spero Therapeutics, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with SPRO, which focuses on combating antibiotic-resistant bacteria, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Spero Therapeutics is a biotech company fighting antibiotic-resistant bacterial infections. Its shares move in sync with clinical trials and regulatory decisions. This specific volatility feeds into the overall market flow, shaping its daily dynamics.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Spero Therapeutics
Spero Therapeutics' year-to-date performance is a story about developing antibiotics to treat resistant infections. Its 12-month market cap is critically dependent on FDA decisions and clinical trial data. Successful approval of its drugs could be a significant milestone in the fight against the growing threat of antibiotic resistance.
Annual dynamics of market capitalization of the market segment - Pharma infections
Spero Therapeutics, Inc. is a biotech company focused on treating resistant bacterial infections. Its stock price is entirely dependent on clinical trial results and regulatory decisions. The chart reflects the high risks and potential for breakthroughs in this critically important area.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Spero Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Spero Therapeutics
Spero Therapeutics is a biotech company fighting antibiotic-resistant bacteria. Its monthly price is extremely volatile and depends on FDA decisions and clinical trial data. The approval or rejection of its drugs by the regulator can cause its price to fluctuate significantly over a short period.
Monthly dynamics of market capitalization of the market segment - Pharma infections
Spero Therapeutics is a biotech company focused on developing new treatments for antibiotic-resistant bacterial infections, one of the most serious threats to global healthcare. The graph below shows the dynamics of the biotech sector, where combating superbugs is a critical task.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Spero Therapeutics is a biotech company fighting antibiotic-resistant bacterial infections. Its shares move not in sync with the market, but rather based on clinical trial results and FDA decisions. The success of a single drug can trigger explosive growth, completely ignoring external market conditions.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Spero Therapeutics
Shares of Spero Therapeutics, a biotech company fighting resistant bacterial infections, reflect the arms race against microbes every week. Price movements reflect clinical trial data and regulatory decisions that could approve new life-saving antibiotics.
Weekly dynamics of market capitalization of the market segment - Pharma infections
Spero Therapeutics fights antibiotic-resistant bacterial infections, a critical yet complex area in the pharmaceutical industry. The chart below will help clarify whether Spero's weekly share price fluctuations reflect its own clinical data or whether they reflect broader sector-wide challenges and advances in the development of new antibiotics.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Spero Therapeutics is a biotech company. Its shares can be highly volatile and sensitive to research news. This chart will help you understand whether Spero is living in its own world of clinical trials, or whether the overall market environment and risk appetite in biotech are actually influencing its stock price.
Market capitalization of the company, segment and market as a whole
SPRO - Market capitalization of the company Spero Therapeutics
Spero's market capitalization tells the story of a biotech company focused on fighting antibiotic-resistant bacterial infections. Its dramatic chart trajectory tells the story of regulatory setbacks and subsequent attempts to regain trust. Its trajectory is a clear example of how an FDA decision can radically change a company's fortunes.
SPRO - Share of the company's market capitalization Spero Therapeutics within the market segment - Pharma infections
Spero Therapeutics is a biopharmaceutical company focused on developing and commercializing new treatments for antibiotic-resistant bacterial infections. Its market capitalization reflects its role in solving this global health problem. The chart below shows how the market values its antibiotic portfolio.
Market capitalization of the market segment - Pharma infections
Spero Therapeutics is a biotech company focused on treating antibiotic-resistant bacterial infections. The chart below shows the market capitalization of this sector. Its dynamics reflect one of the most serious threats to global healthcare, highlighting the importance of Spero's research.
Market capitalization of all companies included in a broad market index - GURU.Markets
Spero Therapeutics is a biotech company developing new antibiotics to combat resistant bacterial infections. Its market cap reflects the hope that its drugs will help solve the antibiotic resistance crisis. Its performance reflects the market's confidence in its ability to address this global threat.
Book value capitalization of the company, segment and market as a whole
SPRO - Book value capitalization of the company Spero Therapeutics
Spero Therapeutics' foundation is its capital, which is dedicated to the development and commercialization of new antibiotics for the treatment of multidrug-resistant bacterial infections. This is a tangible, scientific foundation for solving one of the most pressing healthcare problems. How has this important biotech asset evolved? The chart below shows its dynamics.
SPRO - Share of the company's book capitalization Spero Therapeutics within the market segment - Pharma infections
Spero Therapeutics develops drugs to treat resistant bacterial infections, which requires research laboratories. The chart shows the share of these science-intensive tangible assets, reflecting the physical foundation of its fight against superbugs.
Market segment balance sheet capitalization - Pharma infections
Spero Therapeutics is fighting antibiotic-resistant bacteria. This is a science-intensive process where intellectual property is more important than manufacturing plants. The book value chart shows how "light" this biotech company's capital base is.
Book value of all companies included in the broad market index - GURU.Markets
Spero Therapeutics fights antibiotic-resistant bacterial infections. Its book value is represented by its laboratories and capital invested in the development of new antibacterial drugs. The chart shows the resources on which the company is building its fight against one of the greatest threats to global health.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Spero Therapeutics
Spero's balance sheet is capital. But the market sees it as a superbug fighter. The chart shows the "hope factor": the premium investors are paying for its potential to create new antibiotics that the world desperately needs.
Market to book capitalization ratio in a market segment - Pharma infections
Spero Therapeutics is a biopharmaceutical company developing drugs to treat antibiotic-resistant bacterial infections. This chart shows how much investors believe in its ability to solve this pressing healthcare problem, based on its scientific potential.
Market to book capitalization ratio for the market as a whole
Spero Therapeutics is a biotech company developing new antibiotics to combat drug-resistant superbugs. This is a critically important but commercially challenging area. This chart shows the overall valuation, but how does the market value a company trying to solve a problem that many major pharma companies have neglected?
Debts of the company, segment and market as a whole
SPRO - Company debts Spero Therapeutics
Spero Therapeutics, a biotech company focused on fighting infectious diseases, shows how it funds the development of new antibiotics. This is a complex field with high research costs and challenging market dynamics, requiring a special approach to capital management.
Market segment debts - Pharma infections
Spero Therapeutics is a biotech company focused on combating antibiotic-resistant bacterial infections, one of the most pressing healthcare challenges. This chart shows how the company funds its complex and expensive clinical trials of new antibiotics.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Spero Therapeutics
Spero Therapeutics is a biopharmaceutical company developing drugs to treat antibiotic-resistant infections. This chart shows how dependent it is on debt to fund its vital research. It's a race against time against superbugs, and debt is the fuel.
Market segment debt to market segment book capitalization - Pharma infections
Spero Therapeutics is a biopharmaceutical company focused on treating antibiotic-resistant bacterial infections. This chart shows the overall debt burden in the biotech sector. It helps understand how companies finance their risky clinical trials in this critically important but difficult-to-commercialize area.
Debt to book value of all companies in the market
Spero Therapeutics is a biopharmaceutical company fighting antibiotic-resistant bacterial infections. It is equity-funded and in clinical development. Its overall market leverage is irrelevant to its primary risks, which lie in scientific research and regulatory approvals.
P/E of the company, segment and market as a whole
P/E - Spero Therapeutics
This chart for Spero Therapeutics, a company fighting antibiotic-resistant bacteria, shows the valuation of its developments. The multiple reflects investors' belief that its new antibiotics will become a vital weapon against superbugs, tackling one of the most serious threats to global health.
P/E of the market segment - Pharma infections
Spero's focus on fighting antibiotic-resistant infections is a critical task. This chart shows the average valuation for biopharmaceutical companies. It helps to understand that Spero is valued based on its potential to solve one of the most serious healthcare problems, a risky but potentially highly rewarding mission.
P/E of the market as a whole
Spero Therapeutics is a biopharmaceutical company focused on developing and commercializing new treatments for multidrug-resistant bacterial infections, a critical area of healthcare. This biotech sentiment chart helps understand how the market views the commercial prospects of new antibiotics, which are essential but have historically been difficult to monetize.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Spero Therapeutics
Spero Therapeutics is a biotech company focused on developing drugs to treat multidrug-resistant bacterial infections. This chart reflects investor expectations for its clinical programs in a complex but critically important area of medicine. The trend represents the likelihood of approval for its drugs.
%20P%2FE%20Spero%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Spero-Therapeutics&v=1772513605231 "Chart of the company's future (projected) P/E Spero Therapeutics")
Future (projected) P/E of the market segment - Pharma infections
Spero Therapeutics is a biotech company focused on developing drugs to treat multidrug-resistant bacterial infections. This chart shows profitability expectations for the sector, providing insight into how investors view its drug candidates and the urgent need for new antibiotics.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-infections&v=1772513605235 "Future (projected) P/E graph of the market segment - Pharma infections")
Future (projected) P/E of the market as a whole
Spero Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing new treatments for multidrug-resistant bacterial infections. This chart shows investors' risk appetite. For a company battling the growing threat of superbugs, it reflects the market's willingness to fund the development of new antibiotics.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513605248 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Spero Therapeutics
Spero Therapeutics, Inc. is a biopharmaceutical company focused on developing drugs to treat antibiotic-resistant bacterial infections. The financial result illustrated in this chart is comprised of clinical trial expenses. It illustrates the cost of combating the growing threat of antibiotic resistance.
Profit of companies in the market segment - Pharma infections
Spero Therapeutics is a biopharmaceutical company focused on developing and commercializing novel treatments for antibiotic-resistant bacterial infections. This chart illustrates how companies solving critical healthcare problems like antibiotic resistance can create significant value and impact profitability in the pharmaceutical sector.
Overall market profit
Spero Therapeutics is a biotechnology company focused on developing new treatments for multidrug-resistant bacterial infections. This is an area of enormous medical importance. The company's success depends on scientific breakthroughs and funding. This overall market profitability chart provides the backdrop for decisions about supporting such projects, which are critical to national health.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Spero Therapeutics
Spero Therapeutics is a biopharmaceutical company focused on treating multidrug-resistant bacterial infections. The earnings (loss) forecast in this chart reflects analysts' expectations for clinical trial results in this critical area of medicine.
%20profit%20of%20the%20company%20Spero%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Spero-Therapeutics&v=1772513605305 "Graph of future (projected) profit of the company Spero Therapeutics")
Future (predicted) profit of companies in the market segment - Pharma infections
Spero Therapeutics is a biopharmaceutical company focused on developing and commercializing novel treatments for multidrug-resistant bacterial infections. This chart shows revenue projections for the infectious disease pharmaceuticals sector, allowing one to assess how Spero is addressing the critical problem of antibiotic resistance and its commercial prospects.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-infections&v=1772513605330 "Graph of future (predicted) profits of companies in a market segment - Pharma infections")
Future (predicted) profit of the market as a whole
Spero Therapeutics is a biopharmaceutical company focused on combating antibiotic-resistant infections. Its future depends on the success of clinical trials. This chart, reflecting market sentiment, influences investor willingness to fund long-term, high-risk healthcare projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513605362 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Spero Therapeutics
Spero Therapeutics is a biopharmaceutical company focused on developing new treatments for antibiotic-resistant bacterial infections. This chart shows how investors assess its potential. This valuation is a bet that its drugs will help solve the growing antibiotic resistance crisis.
P/S market segment - Pharma infections
Spero Therapeutics is a biopharmaceutical company focused on developing and commercializing novel treatments for multidrug-resistant bacterial infections. This chart shows the industry average price-to-sales ratio. It reflects investor expectations for Spero's clinical programs and its potential to address the problem of antibiotic resistance.
P/S of the market as a whole
Spero Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for multidrug-resistant bacterial infections. This chart helps understand how the market values companies solving the critical problem of antibiotic resistance, which poses a global threat.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Spero Therapeutics
Spero Therapeutics is a biopharmaceutical company developing drugs to treat antibiotic-resistant bacterial infections. This chart shows its valuation relative to future projected sales. It reflects investor expectations for the success of its clinical programs in combating the growing threat of superbugs.
%20P%2FS%20Spero%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Spero-Therapeutics&v=1772513605514 "The graph of the company's future (projected) P/S Spero Therapeutics")
Future (projected) P/S of the market segment - Pharma infections
Spero Therapeutics is a biopharmaceutical company focused on developing and commercializing novel treatments for multidrug-resistant bacterial infections. This chart reflects investor expectations for its antibiotic portfolio and its ability to address a pressing healthcare need.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20infections&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-infections&v=1772513605519 "Future (projected) P/S market segment graph - Pharma infections")
Future (projected) P/S of the market as a whole
Spero Therapeutics is a biopharmaceutical company focused on treating antibiotic-resistant infections. Its future depends on the success of its clinical trials. This general expectations chart for SPRO is not a direct driver. The company is solving a critical healthcare problem, the demand for which is independent of the state of the economy.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513605537 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Spero Therapeutics
This chart illustrates the financial trajectory of a biotech company. For Spero Therapeutics, which focuses on treating antibiotic-resistant bacterial infections, it reflects revenue from partnerships and funding for the development of its drug candidates.
Sales of companies in the market segment - Pharma infections
Spero Therapeutics is a biopharmaceutical company developing new antibiotics to treat multidrug-resistant bacterial infections. This problem is one of the major threats to healthcare. This chart shows revenues in the pharmaceutical sector. Spero's success could save countless lives and offer a solution to this global crisis.
Overall market sales
Spero Therapeutics is a biotechnology company developing new antibiotics to combat drug-resistant bacterial infections. This problem is one of the main threats to global health. Spero's success is important not only for medicine but also for the entire economy, as antibiotic resistance poses enormous risks.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Spero Therapeutics
Spero Therapeutics is a biopharmaceutical company developing new treatments for multidrug-resistant bacterial infections. Future sales projections depend on the success of its clinical programs.
%20sales%20of%20the%20company%20Spero%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Spero-Therapeutics&v=1772513605619 "Schedule of future (projected) sales of the company Spero Therapeutics")
Future (projected) sales of companies in the market segment - Pharma infections
Spero Therapeutics is a biopharmaceutical company focused on treating antibiotic-resistant bacterial infections. The forecast for the infectious pharmaceutical sector reveals a critical global need. The graph reflects the healthcare system's need for new antibiotics to combat the growing threat of superbugs.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-infections&v=1772513605633 "Schedule of future (projected) sales of companies in the market segment - Pharma infections")
Future (projected) sales of the market as a whole
Spero Therapeutics is a biopharmaceutical company developing drugs to treat antibiotic-resistant bacterial infections. Its success depends on the results of clinical trials. This overall economic activity schedule does not affect the urgent medical need for its products, but it may impact the availability of capital for research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513605637 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Spero Therapeutics
Spero Therapeutics is a biopharmaceutical company focused on developing treatments for antibiotic-resistant bacterial infections. Its financial performance is determined by clinical trial costs. This chart shows the "cost of innovation"—the investment required to bring life-saving drugs to market.
Market segment marginality - Pharma infections
Spero Therapeutics is a biotech company focused on developing new treatments for antibiotic-resistant bacterial infections. Profitability will depend on the success of its drugs. This chart shows the company's operational structure during the R&D phase compared to other companies in this critical field.
Market marginality as a whole
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on treating antibiotic-resistant bacterial infections. This chart reflects average revenue. Compared to this, Spero is betting on solving one of the biggest healthcare problems. The company is not profitable, and its future depends on success in clinical trials.
Employees in the company, segment and market as a whole
Number of employees in the company Spero Therapeutics
Spero Therapeutics is a biopharmaceutical company focused on treating antibiotic-resistant bacterial infections. Its workforce dynamics in this chart reflect its trajectory. Growth was driven by drug advancement in clinical trials, while layoffs may have followed regulatory setbacks or restructuring.
Share of the company's employees Spero Therapeutics within the market segment - Pharma infections
Spero Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for multidrug-resistant bacterial infections. This chart illustrates its scientific focus, reflecting the percentage of microbiologists and infectious disease specialists working on this pressing problem that Spero attracts.
Number of employees in the market segment - Pharma infections
Spero Therapeutics is a biotech company focused on combating multidrug-resistant bacterial infections. This chart highlights the critical importance of antibiotic research. The growth of the research team reflects the global need for new drugs to combat the threat posed by drug-resistant bacteria.
Number of employees in the market as a whole
Spero Therapeutics is a biotech company fighting multidrug-resistant bacterial infections. This is a global health problem. Their development depends on the success of clinical trials, not the overall economic situation. This overall employment chart is irrelevant for a company whose mission is to save lives from a threat that knows no economic boundaries.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Spero Therapeutics (SPRO)
Spero Therapeutics is a biotech company focused on developing new treatments for antibiotic-resistant bacterial infections. This chart shows how the market values companies solving critical healthcare problems. Their high market capitalization per employee reflects the potential of their drugs to combat one of the greatest threats to humanity.
%20of%20the%20company%20Spero%20Therapeutics%20(SPRO)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Spero-Therapeutics-SPRO&v=1772513605876 "Chart of market capitalization per employee (in thousands of dollars) of the company Spero Therapeutics (SPRO)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma infections
Spero Therapeutics fights multidrug-resistant bacterial infections, a critical area of pharmaceuticals. This chart shows the high market premium the company commands for its work on this problem. This high cost per employee reflects the potential of its developments and investors' faith in its scientific team.
%20by%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-infections&v=1772513605891 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma infections")
Market capitalization per employee (in thousands of dollars) for the overall market
Spero Therapeutics is a biopharmaceutical company developing drugs to treat multidrug-resistant bacterial infections. This chart reflects the employee's high performance, as a successful new antibiotic is a critical need for global health.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513605926 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Spero Therapeutics (SPRO)
Spero Therapeutics is a biotech company developing new antibiotics for the treatment of multidrug-resistant bacterial infections. This is a critically important but complex area of R&D. This metric is negative. It reflects how much the company invests in each scientist to create and test new antibiotics that hospitals desperately need.
%20Chart%20Spero%20Therapeutics%20(SPRO)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Spero-Therapeutics-SPRO&v=1772513605981 "Company Profit Per Employee (in thousands of dollars) Chart Spero Therapeutics (SPRO)")
Profit per employee (in thousands of dollars) in the market segment - Pharma infections
Spero Therapeutics (SPRO) is a biotech company focused on treating resistant bacterial infections. As with many biotech companies, this chart is a guide to the future. Currently, profitability is negative. SPRO's success will depend on whether its team can prove the efficacy of its antibiotics and obtain regulatory approval.
%20in%20the%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-infections&v=1772513605999 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma infections")
Profit per employee (in thousands of dollars) for the market as a whole
Spero Therapeutics (SPRO) is a biotech company developing antibiotics to combat superbugs. This is a critically important but complex area. The company is in the R&D stage. This chart reflects the "cost" of maintaining a scientific team trying to create new antibiotics in a challenging market environment.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513606012 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Spero Therapeutics (SPRO)
Spero Therapeutics is a biotech company developing drugs to treat bacterial infections. This chart reflects its status as a clinical-stage R&D company. Lack of revenue is normal. In the future, this metric will become a measure of the commercial success of its next-generation antibiotics.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Spero-Therapeutics-SPRO&v=1772513606030 "Sales chart per company employee Spero Therapeutics (SPRO)")
Sales per employee in the market segment - Pharma infections
Spero Therapeutics is a biotech company specializing in developing new treatments for antibiotic-resistant bacterial infections. During the R&D phase, this metric reflects how effectively their research team generates revenue (e.g., from partnerships) while addressing one of the most pressing problems in medicine.
Sales per employee for the market as a whole
Spero Therapeutics is a clinical-stage biotech company focused on treating antibiotic-resistant infections. It's an R&D company. This chart shows revenue per employee. Predictably, it's zero or very low (from grants), as the entire research staff is focused on drug development, not sales.
Short shares by company, segment and market as a whole
Shares shorted by company Spero Therapeutics (SPRO)
Spero Therapeutics is a biotech company developing new antibiotics to combat resistant bacterial infections. This chart shows bearish bets. Bearish bets point to the commercial complexity of the antibiotic market: the drugs are rarely used, making it difficult to recoup investment, even if they are effective.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Spero-Therapeutics-SPRO&v=1772513606101 "Short Shares Chart for the Company Spero Therapeutics (SPRO)")
Shares shorted by market segment - Pharma infections
Spero Therapeutics is a biotech company focused on treating antibiotic-resistant bacterial infections. This chart shows overall short positions in the biotech sector. A high chart reflects general market skepticism about the sector, possibly due to fears of research failures or funding issues.
Shares shorted by the overall market
Spero (SPRO) is a clinical-stage biotech. Its value reflects the hope for future success. When this indicator of overall pessimism rises, investors are less inclined to hope. They shed money-losing companies in droves that need refinancing for R&D, and SPRO finds itself at the center of the sell-off.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Spero Therapeutics (SPRO)
Spero Therapeutics is a biotech focused on treating complex infections (antibiotics). This is an extremely risky R&D bet. This chart measures the extremes of speculative sentiment. It shows when the stock is "overheated" (overbought) on positive R&D news or "oversold" (bottomed out) amid trial failures or FDA delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Spero-Therapeutics-SPRO&v=1772513606149 "RSI 14 indicator chart for the company's stock Spero Therapeutics (SPRO)")
RSI 14 Market Segment - Pharma infections
Spero (SPRO) is a biotech company, a "superbug" hunter. They are developing a new generation of antibiotics to combat multidrug-resistant (MDR) infections. The "Pharma infections" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It is vital to understand: is SPRO's growth due to their R&D, or is the entire biotech sector "overheated"?
RSI 14 for the overall market
For Spero Therapeutics (SPRO), a biotech company, this graph is a lifeline. Its survival depends on "cash for research." During periods of market euphoria, investors are willing to generously fund risky but promising R&D projects. During periods of panic, the cash tap is turned off, and SPRO risks running out of funds for drug development.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast SPRO (Spero Therapeutics)
Spero Therapeutics is a biotech company focused on treating infections caused by multidrug-resistant bacteria. This chart shows the average target price. Analysts' forecasts are based on clinical data for its antibiotic portfolio and its success in obtaining FDA approval.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-SPRO-Spero-Therapeutics&v=1772513606221 "A chart showing analyst consensus forecasts for the expected stock price. SPRO (Spero Therapeutics)")
The difference between the consensus estimate and the actual stock price SPRO (Spero Therapeutics)
Spero is a biopharmaceutical company tackling a major threat: developing next-generation antibiotics to combat superbugs (MDRs). This chart shows the upside and downside potential analysts see in the stock. It measures the gap between the price and forecast, reflecting their confidence in the company's R&D portfolio.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-SPRO-Spero-Therapeutics&v=1772513606238 "A chart showing the difference between the consensus forecast and the actual stock price. SPRO (Spero Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Pharma infections
Spero Therapeutics is a biotech company focused on fighting "superbugs." It develops new antibiotics to treat complex infections. This chart displays analysts' overall expectations for the pharmaceutical sector. It shows whether experts believe the market for new antibiotics is commercially viable.
Analysts' consensus forecast for the overall market share price
Spero Therapeutics (SPRO) is a biopharmaceutical company solving the "superbugs" problem. They are developing next-generation antibiotics to treat infections resistant to existing drugs. This chart shows the overall risk appetite, reflecting the market's willingness to finance the complex and low-margin antibiotic development sector.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Spero Therapeutics
Spero Therapeutics is a biotech company waging war on superbugs. They are developing a new generation of antibiotics (in tablet form) to treat complex infections resistant to existing drugs. This chart is a summary of their R&D progress. Its dynamics depend entirely on their (very risky) clinical trial data and their complex dialogue with the FDA.
AKIMA Market Segment Index - Pharma infections
Spero Therapeutics is a biotech company focused on treating multidrug-resistant bacterial infections. This is a critically important but complex area of pharmaceuticals. This chart shows the average index for the infectious diseases sector. It provides investors with a benchmark for how Spero's performance compares to the sector average.
The AKIM Index for the overall market
Spero Therapeutics is a biotech company focused on developing antibiotics for the treatment of rare and severe infections. Its key asset is Tebipenem. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this company, operating in the antibiotics sector, which is difficult to commercialize, compares to overall trends.
